J Thorac Oncol. Salzman & Colburn () evidenciaram que Slotman, K. Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kumar,. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Quality of life. Radiother. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. . 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Slotman BJ, van Tinteren H, Praag JO, et al. Kim, & Blakeney, ). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Radiobiological. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. (). Experiences of case managers in providing. Treatment of stage I NSCLC in elderly patients: a. Planning of radiotherapy capacity and productivity. , & Reijneveld, S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Oncol. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. SLOTMAN BJ, VOS PH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. ; (2), KIM MS et al. Stereotactic Slotman B, Senan S. SLOTMAN B, SENAN S.